Jupiter Neurosciences Files Q2 2025 10-Q
Ticker: JUNS · Form: 10-Q · Filed: 2025-08-19T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceutical
TL;DR
Jupiter Neurosciences filed its Q2 2025 10-Q. Financials are in.
AI Summary
Jupiter Neurosciences, Inc. filed its 10-Q for the period ending June 30, 2025. The filing details financial performance and operational updates for the company, which is involved in the pharmaceutical preparations sector. Key financial data and disclosures relevant to investors are included.
Why It Matters
This filing provides investors with the latest financial health and operational status of Jupiter Neurosciences, Inc., crucial for understanding the company's trajectory in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Jupiter Neurosciences faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-06-30 — Reporting Period End (Quarterly financial data is reported as of this date.)
- 2025-08-19 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- JUPITER NEUROSCIENCES, INC. (company) — Filer
- 20250630 (date) — Reporting Period End Date
- 20250819 (date) — Filing Date
- 001-41265 (other) — SEC File Number
- Jupiter Orphan Therapeutics, Inc. (company) — Former Company Name
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is for the period ending June 30, 2025.
What is the company's SEC file number?
The SEC file number for Jupiter Neurosciences, Inc. is 001-41265.
What was the former name of Jupiter Neurosciences, Inc.?
The former name of Jupiter Neurosciences, Inc. was Jupiter Orphan Therapeutics, Inc.
On what date was this 10-Q filed?
This 10-Q was filed on August 19, 2025.
What is the Standard Industrial Classification code for Jupiter Neurosciences, Inc.?
The Standard Industrial Classification code for Jupiter Neurosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
From the Filing
0001641172-25-024684.txt : 20250819 0001641172-25-024684.hdr.sgml : 20250819 20250818190603 ACCESSION NUMBER: 0001641172-25-024684 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250819 DATE AS OF CHANGE: 20250818 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JUPITER NEUROSCIENCES, INC. CENTRAL INDEX KEY: 0001679628 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 474828381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41265 FILM NUMBER: 251229269 BUSINESS ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: (561) 406-6154 MAIL ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: Jupiter Orphan Therapeutics, Inc. DATE OF NAME CHANGE: 20160713 10-Q 1 form10-q.htm 10-Q false Q2 --12-31 0001679628 0001679628 2025-01-01 2025-06-30 0001679628 2025-08-18 0001679628 2025-06-30 0001679628 2024-12-31 0001679628 us-gaap:RelatedPartyMember 2025-06-30 0001679628 us-gaap:RelatedPartyMember 2024-12-31 0001679628 us-gaap:SeriesAPreferredStockMember 2025-06-30 0001679628 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001679628 2025-04-01 2025-06-30 0001679628 2024-04-01 2024-06-30 0001679628 2024-01-01 2024-06-30 0001679628 us-gaap:CommonStockMember 2024-12-31 0001679628 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001679628 JUNS:ReceivablesForSaleOfStockMember 2024-12-31 0001679628 us-gaap:RetainedEarningsMember 2024-12-31 0001679628 us-gaap:CommonStockMember 2025-03-31 0001679628 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001679628 JUNS:ReceivablesForSaleOfStockMember 2025-03-31 0001679628 us-gaap:RetainedEarningsMember 2025-03-31 0001679628 2025-03-31 0001679628 us-gaap:CommonStockMember 2023-12-31 0001679628 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001679628 JUNS:ReceivablesForSaleOfStockMember 2023-12-31 0001679628 us-gaap:RetainedEarningsMember 2023-12-31 0001679628 2023-12-31 0001679628 us-gaap:CommonStockMember 2024-03-31 0001679628 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001679628 JUNS:ReceivablesForSaleOfStockMember 2024-03-31 0001679628 us-gaap:RetainedEarningsMember 2024-03-31 0001679628 2024-03-31 0001679628 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001679628 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001679628 JUNS:ReceivablesForSaleOfStockMember 2025-01-01 2025-03-31 0001679628 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001679628 2025-01-01 2025-03-31 0001679628 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001679628 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001679628 JUNS:ReceivablesForSaleOfStockMember 2025-04-01 2025-06-30 0001679628 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001679628 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001679628 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001679628 JUNS:ReceivablesForSaleOfStockMember 2024-01-01 2024-03-31 0001679628 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001679628 2024-01-01 2024-03-31 0001679628 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001679628 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001679628 JUNS:ReceivablesForSaleOfStockMember 2024-04-01 2024-06-30 0001679628 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001679628 us-gaap:CommonStockMember 2025-06-30 0001679628 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001679628 JUNS:ReceivablesForSaleOfStockMember 2025-06-30 0001679628 us-gaap:RetainedEarningsMember 2025-06-30 0001679628 us-gaap:CommonStockMember 2024-06-30 0001679628 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001679628 JUNS:ReceivablesForSaleOfStockMember 2024-06-30 0001679628 us-gaap:RetainedEarningsMember 2024-06-30 0001679628 2024-06-30 0001679628 us-g